Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017


News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bayer : Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
06/23/2017 | 02:44pm CEST
  • Positive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Approval could provide first treatment advance in nearly a decade / Final decision from the European Commission anticipated within the next two months

  • Berlin, June 23, 2017- Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended regorafenib for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar®(sorafenib). Regorafenib is the first and only treatment that has demonstrated a significant improvement in overall survival in second-line HCC patients who previously had no other options. The final decision of the European Commission on the marketing authorization is expected in the coming months. The anti-cancer medication from Bayer is already approved under the brand name Stivarga®in more than 90 countries worldwide for the treatment of metastatic colorectal cancer (CRC), including countries of the EU, and in more than 80 countries globally for the treatment of metastatic gastrointestinal stromal tumors (GIST), including countries of the EU. The product recently gained approval in the U.S. for second-line treatment of HCC and additional regulatory filings for Stivarga in HCC are under review in countries around the world, including China.

    "Liver cancer is one of the leading cancer-related causes of death in Europe. Nexavar, as the first and only approved systemic treatment for HCC, has been a major advance in this field, but effective second-line treatment options are urgently needed for patients," said Robert LaCaze, Executive Vice President and Head of the Oncology Strategic Business Unit at Bayer. "The positive opinion for regorafenib in Europe is great news for patients as it supports our efforts to make this treatment available to as many patients as possible in the second-line HCC setting and offers a treatment plan with two therapies that both have shown to improve overall survival."

    Liver cancer is often more difficult to treat than other cancers with an annual mortality rate of 48,000 in in the EU. Globally, it is the second leading cause of cancer-related deaths.

    The positive opinion is based on data from the international, multicenter, placebo-controlled Phase III RESORCE [REgorafenib after SORafenib in patients with hepatoCEllular carcinoma; NCT 01774344] trial, which investigated patients with HCC whose disease had progressed during treatment with Nexavar. In the trial, regorafenib plus best supportive care (BSC) was shown to provide a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo plus BSC (HR 0.63; 95% CI 0.50-0.79; p

    About Hepatocellular Carcinoma
    Hepatocellular carcinoma, or HCC, is the most common form of liver cancer representing approximately 70-85 percent of liver cancer worldwide. Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related deaths globally. More than 780,000 cases of liver cancer are diagnosed worldwide each year (52,000 in the European Union, 501,000 in the Western Pacific region and 30,000 in the United States) and the incidence rate is increasing. In 2012, approximately 746,000 people died of liver cancer including approximately 48,000 in the European Union, 477,000 in the Western Pacific region and 24,000 in the United States.

    About Regorafenib (Stivarga®)
    Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R).

    Regorafenib is approved under the brand name Stivarga®in more than 90 countries worldwide, including the U.S., countries of the EU, China and Japan for the treatment of metastatic colorectal cancer (mCRC). The product is also approved in over 80 countries, including the U.S., countries of the EU, China and Japan, for the treatment of metastatic gastrointestinal stromal tumors (GIST). It was recently approved in the U.S. for second-line treatment of HCC. Additional regulatory filings for Stivarga in HCC are under review in countries around the world, including China.

    In the EU, Stivarga is indicated for the treatment of adult patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy, as well as for the treatment of adult patients with unresectable or metastatic GIST who progressed on or are intolerant to prior treatment with imatinib and sunitinib.

    Regorafenib is a compound developed by Bayer. In 2011, Bayer entered into an agreement with Onyx, now an Amgen subsidiary, under which Onyx receives a royalty on all global net sales of regorafenib in oncology.

    About Oncology at Bayer
    Bayer is committed to delivering science for a better life by advancing a portfolio of innovative cancer treatments. The oncology franchise at Bayer currently includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways, with the potential to impact the way that cancer is treated.

    Bayer: Science For A Better Life

    Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go towww.bayer.com.

    Our online press service is just a click away:press.bayer.com
    Follow us on Facebook:http://www.facebook.com/pharma.bayer
    Follow us on Twitter:https://twitter.com/BayerPharma

    Find more information atwww.pharma.bayer.com.

    Forward-Looking Statements
    This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website atwww.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG published this content on 23 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 June 2017 12:44:05 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
06/23 BAYER : Receives Positive CHMP Opinion for regorafenib for the Second-Line Syste..
06/22 COVESTRO : Patent Issued for Electrocatalyst, Electrode Coating and Electrode fo..
06/22 BAYER : Patent Issued for Stable, Concentrated Herbicidal Compositions (USPTO 96..
06/22 Ethisphere Teams with Leaders from Top Companies to Drive Business Ethics
06/22 COVESTRO : U.S. Patents Awarded to Inventors in West Virginia (June 22)
06/22 COVESTRO : U.S. Patents Awarded to Inventors in Georgia (June 22)
06/21 Sore Throat Remedies Market 2017 - Pfizer, Novartis, Bayer AG, AstraZeneca, P..
06/20 Novartis eye drug works with fewer injections than rival
06/20 COVESTRO : LLC President to Co-Lead Sustainable Pittsburgh’s ‘CEOs f..
06/18 BAYER : Selects Young Leaders to Help Address Global Food Security Challenges
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 European Ad Com backs Bayer's regorafenib for second-line liver cancer
06/22 Bayer AG (BAYZF) Presents At Citi European Healthcare Conference - Slideshow
06/20 Novartis wet AMD candidate brolucizumab matches Eylea in late-stage studies w..
06/18 MONSANTO : Majority Of Polled Americans Oppose Bayer Acquisition (Will It Matter..
Financials (€)
Sales 2017 49 998 M
EBIT 2017 9 698 M
Net income 2017 5 742 M
Debt 2017 10 783 M
Yield 2017 2,34%
P/E ratio 2017 18,62
P/E ratio 2018 17,32
EV / Sales 2017 2,24x
EV / Sales 2018 2,09x
Capitalization 101 301 M
More Financials
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 118 €
Spread / Average Target -3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER23.58%113 105
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results